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Abstract 
Currently available premixed insulins provide basal and prandial glucose control; however, 
they have an intermediate-acting prandial insulin component and do not provide as effective 
basal coverage as true long-acting insulins. The limitations of premixed insulins additionally 
relate to the physicochemical incompatibility of their individual components, coupled with the 
inflexibility of adjustment. By contrast, the molecular structure of the two components of the 
co-formulation of insulin degludec with insulin aspart (IDegAsp), a novel insulin preparation, 
allows these two molecules to co-exist without affecting their individual pharmacodynamic 
profiles. The IDegAsp clinical trial programme finds that in people with type 2 diabetes 
mellitus (T2DM), once- and twice-daily dosing provides similar overall glycaemic control 
(HbA1c) to current modern insulins, but with lower risk of nocturnal hypoglycaemia. In prior 
insulin users, such glycaemic control was achieved with lower or equal insulin doses than 
with other basal + meal-time or premix insulin regimens. Clinically, in insulin-naïve patients 
with T2DM, IDegAsp can be started once or twice daily, based on individual need. People 
switching from more than once-daily basal or premix insulin therapy can be converted unit-to-
unit to once-daily IDegAsp, although this strategy should be assessed by the physician on an 
individual basis. IDegAsp offers physicians and people with T2DM a simpler insulin regimen 
than other available basal-bolus or premix-based insulin regimens, with a stable basal 
coverage throughout the day, a lower rate of hypoglycaemia, and some flexibility in injection 
timing compared with premix insulins.  
(239/250 words)  
 
Review criteria 
How did you gather, select and analyse the info you considered in your review?’ (2 or 3 short 
sentences; 70 words) 
Findings from key studies of the IDegAsp clinical trial programme were chosen as a basis for 
the clinical guidance provided here. The authors had access to all presented and published 
studies, and the restricted availability of IDegAsp until recently has prevented significant 
studies outside the development programme. All phase 2 and 3 studies are included. 
 
Message for the clinic  
What is the take-home message for the clinician?’ (2 or 3 short sentences; 70 words). 
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IDegAsp is a novel co-formulation of insulin degludec (IDeg) and insulin aspart (IAsp). It can 
be used once or twice daily, providing reliable coverage of both basal and prandial insulin 
requirements with a lower risk of hypoglycaemia than current insulin options. It permits 
greater flexibility in timing of doses and the possibility of equivalent glycaemic control as 
basal-bolus, but with the advantage of reduced injection burden, thus simplifying treatment 
regimens. 
(70/70 words) 
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Introduction 
Type 2 diabetes mellitus (T2DM) is characterised by a progressive decline in β-cell function, 
necessitating the introduction of sequential glucose-lowering therapies, including insulin, to 
achieve or maintain glycaemic targets [1–3]. 
Stepwise optimisation involving insulin therapy is often delayed (‘clinical inertia’), sometimes 
for many years [3]. Many reasons have been identified for this delay, including the perception 
by both physicians and people with diabetes mellitus of the increased burden of multiple 
injections and blood glucose monitoring, the complexity of multi-medication regimens, and 
concerns about the risks of hypoglycaemia and body weight gain [2, 3]. Physicians also 
express concerns over consequent decreased adherence to therapy [4]. 
The introduction of longer-acting basal insulins and, more recently, the combination of a long-
acting flat basal insulin with a fast-acting prandial insulin, provides some advantages over the 
combination of intermediate- and fast-acting insulin in current premixed products [5,6]. 
Potentially this combination addresses some of these concerns through dose reduction and 
lower injection burden without loss of efficacy and perhaps with less hypoglycaemia. These 
issues are considered below in the context of the insulin degludec/insulin aspart co-
formulation (IDegAsp).  
 
Unmet clinical need 
Current premixed insulins, which contain both fast- and intermediate-acting insulin 
components, aim to provide both basal and meal-time glucose control. Existing premixes are 
a mixture of unbound fast-acting insulin, and fast-acting insulin, which is protaminated to 
delay absorption. They have an intermediate duration of action and thus do not provide the 
basal coverage seen with true long-acting basal insulins. It has not been possible to produce 
co-formulations of the first-generation long-acting insulin analogues (insulins glargine and 
detemir) with fast-acting insulins, either due to physicochemical incompatibility or without 
affecting their individual pharmacokinetic (PK) and pharmacodynamic (PD) profiles [7,8]. 
Existing premixed insulins, most commonly in a 30/70 fast/basal ratio (thus ‘biphasic’), utilise 
either human insulin (BHI30) or analogue insulins, such as biphasic insulin aspart (BIAsp 30) 
or insulin lispro (75/25) [9]. The advantage of fewer daily injections with premixed insulins 
compared with basal + meal-time regimens [9] is, to some extent, offset by lack of flexibility 
of individual dose adjustment of the meal-time and basal components. There is some 
evidence to suggest that when administered once or twice daily, premixed insulins 
demonstrate a greater reduction in glycated haemoglobin (HbA1c) when compared with basal 
8/25 
insulin analogues, but at the cost of increased risk of hypoglycaemia and weight gain 
[2,10,11], which may affect treatment adherence [4]. The outstanding need was then for a co-
formulated insulin retaining the fast-acting analogue advantage at meal-times with a truly flat 
24-h basal coverage. 
 
Physicochemical properties of IDegAsp 
The co-formulation of IDeg and IAsp in IDegAsp is a clear, colourless, neutral pH solution 
[12]. The two components do not interact and remain molecularly separate, as shown in 
Figure 1A [13]. Being fully dissolved, resuspension to homogeneity before injection is not 
necessary, which to date is not possible with other current insulin analogues. 
Insulin glargine (IGlar) is presented as a solution at pH 4, and consequently co-formulation 
with meal-time insulins (usually formulated to neutral pH) is not possible [14]. Following 
subcutaneous injection, IGlar forms microprecipitates and must be re-dissolved prior to 
absorption, rendering its absorption inherently variable [15]. The early pharmacodynamic 
action of IAsp is markedly blunted and its time–action profile prolonged when mixed with 
insulin detemir (IDet), compared with a separate injection of these analogues [7]. This is as a 
result of the different formulation needed to maintain the physicochemical stability of these 
analogues.  
The molecular structure of the two components of IDegAsp allows them to co-exist without 
affecting their individual PK and PD profiles [13]. The basal component, IDeg, exists in the 
form of stable di-hexamers in the pharmaceutical preparation, forming long multi-hexamer 
chains after subcutaneous administration (Figure 1B). Subsequently, continual release of 
IDeg monomers from the ends of the chains ensures a flat PK/PD profile, lasting long 
enough to meet basal insulin requirements over 24 h once at steady state [16]. In contrast, 
IAsp in IDegAsp exists as hexamers in the vial, which rapidly dissociate into monomers after 
subcutaneous administration, providing a near-physiological meal-time concentration profile 
[14]. This has been confirmed by size exclusion chromatography, in conditions simulating 
pharmaceutical preparations as well as after subcutaneous administration, clearly showing 
the existence of two separate components that do not affect each other’s PK/PD profile, 
either in solution or once injected [13]. Furthermore, a clamp study carried out in people with 
type 1 diabetes mellitus (T1DM) at steady state demonstrated the basal and meal-time 
effects of the two components in a dose-dependent manner [14].  
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Pharmacokinetic/pharmacodynamic properties of IDegAsp 
The PK and PD properties of IDegAsp are summarised in Table 1. The basal component, 
IDeg, is characterised by a PK half-life of > 25 h, and thus an ultra-long duration of action 
(> 42 h) [17]. The flat profile means that the within-person, within-day variability in glucose-
lowering effect is four times lower compared with IGlar [18]. The consistent insulin absorption 
rate in combination with a flat profile would be predicted to be associated with a decreased 
risk of hypoglycaemia. 
A randomised, single-centre, double-blind, glucose clamp study in a cohort of 33 people with 
T1DM found that IDegAsp has a clear glucose-requirement-to-dose relationship [19] that is 
observed for both the basal and meal-time components.  
Modelling of glucose infusion rate during 24-h dosing in a glycaemic clamp setting, based on 
a study of once-daily dosing at steady state, suggests that total glucose-lowering effect was 
independent of daily dosing frequency. Therefore, the glucose-lowering effect of IDegAsp is 
dependent on total dose given, whether one or more injections per day are used (Figure 2) 
[14]. As a result, the Summary of Product Characteristics suggests that if a dose is missed, it 
can be taken with the next main meal of that day [12]. After any dose change, including 
commencing the insulin, steady-state plasma levels of the degludec component are reached 
in 2–3 days, and plasma insulin does not accumulate further (‘stacking’) [20], with the results 
from the 24-h elimination rate equalling the 24-h absorption rate [21].  
As the clinical pharmacology profiles of the IDeg and IAsp components of IDegAsp are 
distinct, evidence from PK and PD studies of IDeg and IAsp development programmes can 
be applied to IDegAsp. Moreover, no clinically relevant differences in the pharmacodynamics 
of IDegAsp in older people were found following a phase 1, double-blind crossover trial of 
IDegAsp in young adults (18–35 years of age) and older (≥ 65 years of age) people with 
T1DM [22]. In addition, no clinically relevant differences have been observed in the PK or PD 
of IDeg or IAsp in patients with renal or hepatic impairment [23–25]. Together, these findings 
indicate that IDegAsp may be used in people with renal impairment, and in older people 
(≥ 65 years old), with the usual clinical cautions over differences in insulin sensitivity in these 
populations. However, glucose monitoring should be optimised and insulin dose adjusted on 
an individual basis [12]. 
 
Clinical evidence in T1DM 
In T1DM, IDegAsp has been assessed in a single study (Table 2). Here, IDegAsp was given 
once daily in a regimen with IAsp at other meals and compared with an IDet + IAsp multiple 
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injection regimen. IDegAsp was non-inferior to IDet + IAsp for reduction in HbA1c despite a 
13% lower insulin dose (Table 2) [26]. Per protocol, the meal at which IDegAsp was dosed 
could be changed during the study; however, few participants chose to do so. Lower rates of 
hypoglycaemia were also observed in a 26-week extension of the same study [(IDegAsp 
once daily + IAsp at meal-times vs IDet once or twice daily + IAsp at meal-times) [27].  
 
Clinical evidence in T2DM 
Efficacy and safety of IDegAsp once daily vs. IGlar once daily: Phase 2 data  
In an insulin-naïve population, once-daily, pre-dinner IDegAsp provides similar overall 
(HbA1c) glycaemic control at 16 weeks compared with IGlar, despite a lower daily insulin 
dose, but with better control of post-evening meal glucose (Table 2) [28]. In a subpopulation 
using continuous glucose monitoring for 72 h before the last visit, people using IDegAsp had 
significantly lower post-evening meal glucose excursions than those using IGlar. These 
individuals also had less nocturnal hypoglycaemia, which may be partly explained by the 
smaller fluctuation in nocturnal glucose levels, attributable to the consistent 
pharmacodynamics effect of IDeg [29]. 
Once-daily IDegAsp use in T2DM: Phase 3 data 
In Japan, IDegAsp administered once daily to insulin-naïve people with T2DM demonstrated 
superiority to IGlar in lowering HbA1c (difference –0.28 [95% confidence interval (CI) –0.46; –
0.10] %-units) with similar end-of-trial fasting plasma glucose (FPG). The estimated rate of 
nocturnal confirmed hypoglycaemia was numerically lower by 25%; however, it was not 
statistically significant (Table 2). Daily insulin dose and adverse events did not differ [30].  
Twice-daily IDegAsp use in T2DM 
IDegAsp treatment in insulin-naïve people 
In a global study in insulin-naïve people comparing twice-daily IDegAsp with twice-daily 
BIAsp 30, there was no difference in HbA1c, despite FPG being 1.0 mmol/l lower (p < 0.001). 
However, in this study there was a 75% reduction in nocturnal confirmed hypoglycaemia in 
favour of IDegAsp, together with a 54% reduction in any-time hypoglycaemia (p < 0.001) 
(Table 2) [31].  
IDegAsp treatment in prior insulin users  
In studies comparing twice-daily administration of IDegAsp with BIAsp 30, one in a global 
population and one in an Asian population, IDegAsp was non-inferior to BIAsp 30 for change 
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in HbA1c, but superior in lowering FPG and at a lower daily insulin dose (Table 2) [29, 30]. 
IDegAsp demonstrated a 32% reduction in confirmed hypoglycaemia rate (p = 0.005) and a 
73% reduction in rate of nocturnal confirmed hypoglycaemia (p < 0.001) [5]. In the Asian 
population, there was no effect on any-time (confirmed) hypoglycaemia and the rate ratio for 
nocturnal confirmed hypoglycaemia (reduction of 33%) did not meet statistical significance 
[6]. 
A patient-level combined analysis of the global and Asian studies found that IDegAsp was 
associated with a greater reduction in FPG from baseline (p < 0.001) and less weight gain 
(p = 0.012). The rates of overall confirmed, nocturnal confirmed, and severe hypoglycaemic 
events were, respectively, 19% (p = 0.03), 57% (p < 0.001) and 39% (not significant [NS]) 
lower with IDegAsp compared with BIAsp 30, but heterogeneity between study results limits 
the robustness of this approach. Furthermore, the lower risk of hypoglycaemia was more 
pronounced during the maintenance period (> 16 weeks) in the two studies. The analysis 
also found that daily insulin doses at end of trial were 16% lower for IDegAsp than BIAsp 30 
(estimated dose ratio [95% CI]: 0.84 [0.80; 0.89], p < 0.0001) [32]. 
Twice-daily IDegAsp vs. basal + meal-time insulin therapy in prior insulin users  
Comparing two treatment-optimisation regimens from basal-only therapy, IDegAsp (twice 
daily) showed final HbA1c comparable to the one achieved with a meal-time + basal regimen 
of IDeg + IAsp (7.0% and 6.8%, NS) [33]. Although non-inferiority for IDegAsp was not 
achieved, insulin dose was 12% lower using combination insulin, while both confirmed and 
nocturnal hypoglycaemia rates were 19% and 20% lower, respectively (Table 2) [33]. 
Additionally, although the health-related quality of life questionnaire (SF-36v2) revealed no 
difference between treatment groups for physical scores, there was a higher overall change 
from baseline for mental scores with IDegAsp than for IDeg + IAsp, potentially driven by 
change from baseline in the mental health domain score for social functioning, which was 
significantly higher for IDegAsp (end-of-treatment difference 2.2 [95% CI 0.3; 4.1]; p < 0.05) 
[33]. 
 
Clinical use of IDegAsp 
Use of IDegAsp in clinical practice 
Administration 
As currently licensed in Europe, IDegAsp can be used once daily or twice daily and allows for 
flexibility in the timing of administration as long as it is dosed with the main meal(s) [12]. 
IDegAsp is a clear solution and does not require resuspension. Shelf life is 30 months, 
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provided it is stored below 30°C; it should not be refrigerated. After first opening, IDegAsp 
may be used for up to 4 weeks [12]. Subcutaneous use should be into the abdominal wall, 
upper arm or the thigh (owing to a lack of experience in studies with other injection sites) 
[12]. 
Based on the available data from the IDegAsp clinical trial programme, the following section 
will aim to provide some recommendations for the use of IDegAsp in a clinical setting.  
Beginning IDegAsp in T2DM 
Based on clinical trial data, the recommended usual starting dose is 10 U with the largest 
meal(s), followed by individual dose titration [12]. In clinical trials of IDegAsp, doses were 
titrated up by 2-U increments to achieve an FPG target of < 5.0 mmol/l (< 90 mg/dl), but this 
strategy was reassessed by investigators if hypoglycaemia occurred. If FPG levels 
were < 3.1 mmol/l (<56 mg/dl), reductions of 4 U (or –10% if the dose was > 45 U) were 
advised [29, 30]. In clinical practice, the FPG target and rate of change of doses should be 
individualised according to the clinical characteristics and preferences of the person using 
the insulin [1]. 
The choice of starting IDegAsp once daily or twice daily can also be individualised. Once-
daily administration may be generally preferred, but if two main meals show marked 
hyperglycaemic excursions on prior non-insulin therapy, then twice-daily administration may 
be logical. Switching from once- to twice-daily dosing would be indicated if hyperglycaemia 
persisted at other meal-times throughout the day, or if hypoglycaemia or tight control in the 
period after the injection at the main meal suggested that a reduction in dose of insulin is 
needed. In these circumstances, the daily single dose can be divided into two doses, before 
further dose titration is initiated. 
Optimising insulin treatment with IDegAsp in T2DM 
In clinical practice, a switch of insulin therapy may be indicated, particularly where basal 
insulin is failing to achieve adequate glycaemic control despite active dose titration to FPG 
target. Use of IDegAsp to replace basal insulin alone, either once or twice daily is an option, 
but does require some postprandial monitoring before switching if the timing and number of 
injections is to be optimal. For example, if a change is made from neutral protamine 
Hagedorn basal insulin, then better control before breakfast with IDegAsp may minimise the 
postprandial glucose excursions. 
The switch from other human or analogue premix insulins will usually be indicated by failure 
to obtain adequate control due to hypoglycaemia, lack of insulin action predictability from day 
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to day, or self-measured glucose ranges that indicate an increased risk of hypoglycaemia. 
Most people will be on twice-daily therapy; those switching from a single morning injection of 
premix to twice-daily IDegAsp should be carefully monitored for nocturnal hypoglycaemia. In 
general, a switch from twice-daily premix therapy to IDegAsp will have the same timing of 
injections. However, the properties of IDegAsp are such that people can change the time of 
administration as long as it is dosed with the main meal(s).  
Evidence from clinical trials confirms that people with T2DM can switch from other once-daily 
or twice-daily insulins (basal or premix) to IDegAsp, on a unit-to-unit basis, without risk of 
increase in hypoglycaemia [5,12].  
This was demonstrated in the sub-analysis of people on a high total dose of basal insulin at 
baseline (> 40 U/day and up to 60 U at end of trial) who were switched to 1:1 IDegAsp once 
daily; after the first 4 weeks of switching, IDegAsp was not associated with an increased rate 
of hypoglycaemia [34].  
Glucose control responses, including hypoglycaemia, to changing insulins vary markedly 
between individuals, so the usual clinical advice regarding switching regimens is 
recommended when switching to IDegAsp. This advice includes close glucose self-
monitoring and special care when risk of hypoglycaemia may be particularly important (e.g. 
when driving). Adjustment of concurrent glucose-lowering therapies may also be needed 
[12]. If the reason for switching is recurrent hypoglycaemia or large day-to-day variation in 
FPG, it may be prudent to reduce the dose of IDegAsp by 10–20%, as trial data indicate that 
IDegAsp gives similar glycaemic control at lower doses than BIAsp 30 or basal + meal-time 
injection regimen (Table 2) [5,6,32,33]. However, if the reason for switching is uncontrolled 
hyperglycaemia, then no dose reduction is needed. 
People who have previously been receiving once-daily basal or premixed/self-mixed insulin 
may be started on twice-daily doses of IDegAsp by splitting the prior total dose into two equal 
doses of IDegAsp, although meal pattern may suggest a different balance of doses [6,33,35].  
Several factors may influence the need for switching treatment regimens, including lack of 
adherence to therapy, complexity of multidrug regimens and the higher risk of hypoglycaemia 
[2,3]. When switching from basal + meal-time bolus insulin regimen to IDegAsp, careful 
assessment of the conversion of insulin doses will need to be based on individual need, with 
consideration of meal pattern, physical activity and self-measurement profiles. In general, 
conversion with the total basal dose may be administered twice daily.  
General insulin management issues 
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Steady-state serum IDeg concentrations are reached after 2–3 days [12]. With IDegAsp, 
meal-time insulin stacking can be of concern and the duration of action of IAsp (3–5 h) [36] 
should be taken into consideration if IDegAsp is being used as a multiple injection regimen, 
particularly when used with BIAsp 30, where a ‘shoulder effect’ has been observed between 
6 and 12 h due to the overlapping effects of the IAsp in IDegAsp and protaminated Asp in 
BIAsp 30 [19].  
Studies of IDeg alone have demonstrated flexibility of time of daily injection [37]. Accordingly, 
the European label for IDegAsp recognises that some meal-time flexibility is acceptable [12], 
with the proviso that it is given with the largest meal. It is expected that injection flexibility 
may help with adherence to an IDegAsp insulin regimen.  
IDegAsp treatments may be titrated weekly; IDeg serum concentrations take 2–3 days to 
reach steady state [12], after which the average of the 3 days’ plasma glucose 
measurements can be taken. Appropriate dosing of the basal component is best indicated by 
self-measured FPG for either regimen, as pre-evening meal levels may reflect uncontrolled 
glucose excursions after the midday meal. The success of the prandial component is best 
judged by postprandial glucose levels (0–120 minutes after the beginning of the meal), and 
by those before the next meal. Again, as with all insulin regimens, the occurrence of 
hypoglycaemia, or risk of it, will modulate insulin dose adjustment, depending in part on the 
time of day it occurs.  
IDegAsp has the potential to benefit a wide range of people with T2DM, but some may have 
particular treatment needs. Thus, if FPG is within the individualised target range, but meal-
time control is an issue, perhaps as indicated by high HbA1c on basal insulin or premix insulin 
after optimisation, then IDegAsp can be useful. Those for whom the basal insulin dose is 
adequate, as indicated by FPG levels – but who are unable to achieve HbA1c target levels, 
due to large day-to-day pre-breakfast glucose variability and fear of nocturnal hypoglycaemia 
– may also benefit from the flatter night-time profile of IDegAsp. Anyone on premix insulin 
having hypoglycaemia due to overlap of the meal insulin component and variability of the 
protaminated components would also be a logical candidate.  
Finally, people on any insulin regimen who previously would require optimisation with a full 
basal + meal-time bolus insulin regimen may also be offered twice-daily IDegAsp [12], 
although care needs to be taken with glucose excursions at the third main meal. At present, 
the European licence extends only to twice-daily injection, even while the data of the PK/PD 
studies could be extrapolated to suggest that a higher injection number would not be 
detrimental, and may even facilitate the achievement of glycaemic targets, provided the 
relevant meal intervals were maintained.  
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Summary 
Most patients with T2DM will eventually need insulin. Intensification of the dose and the 
change of regimen is important to maintain individualised glycaemic targets. Concerns over 
complicated injection regimens, hypoglycaemia and weight gain, among other factors, can 
unnecessarily delay treatment intensification. There is an unmet need for a better, simpler 
insulin regimen that provides both basal and prandial insulin control that may lead to 
improved treatment adherence. 
IDegAsp is a novel combination of IDeg and IAsp in a single injection that is able to provide a 
flat and stable 24-h basal insulin coverage and bolus meal-time insulin control with reduced 
injection burden compared with standard basal and bolus therapy. This feature makes 
IDegAsp particularly applicable for use in patients with T2DM. 
Clinical trials with a treat-to-target design have demonstrated that IDegAsp is associated with 
effective glycaemic control and reduced rates of hypoglycaemia in comparison with other 
insulin analogues, which may allow for easier initiation and optimisation of insulin therapy. 
IDegAsp may be added to oral glucose-lowering therapy. The decision to move from once-
daily to twice-daily dosing is guided by preferences and meal-time glucose excursions, but 
may also require some postprandial monitoring in order to optimise the timing and number of 
injections on an individual basis.  
IDegAsp twice daily has been shown to provide effective HbA1c control and superior 
reductions in FPG compared with BIAsp 30 twice daily, while achieving lower rates of 
hypoglycaemia. Clinical data further indicate that IDegAsp twice daily offers a simpler 
alternative to basal-bolus treatment in patients who require intensification of basal insulin 
regimens. In conclusion, IDegAsp is a novel co-formulation that may offer patients with 
progressive T2DM a simpler, injectable insulin regimen with fewer injections than with basal-
plus or basal-bolus insulin therapy. IDegAsp offers flexibility in administration to suit individual 
lifestyle needs compared with existing premixed insulins in terms of differences in timing of 
meals and dietary patterns. Finally, IDegAsp twice daily may help to improve adherence in 
patients who may find the use of more complex regimens challenging. 
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Figures and Tables 
Table 1 Summary of the pharmacokinetic and pharmacodynamic properties of IDegAsp 
Property IDegAsp 
Formulation  70%/30% co-formulation of IDeg and IAsp [12]
 
Dosing Once- or twice-daily with any main meal(s) [12]. Timing of meals not 
important if interval >4 hours. Timing of meals can vary between days 
Mechanism of action IDeg di-hexamers form a depot of soluble multi-hexamers from which 
monomers continuously and slowly dissociate; IAsp hexamers dissociate 
promptly into monomers [38]
 
(Figure 1) 
Steady state Reached 2–3 days after any dose change [20] 
 
Glucose-lowering effect 
 
Meal-time profile of IAsp, and stable glucose-lowering effect due to IDeg 
once in steady state [12,14]
 
Onset of action IAsp component ~14 minutes (due to the IAsp component), with meal at 
72 minutes [12] 
Duration of action > 30 h for basal component
 
[14]
 
Exposure and dose-
proportionality 
At steady state, exposure to the IDeg component remained similar from 
day to day [20]. Total exposure increases proportionally with dose and is 
independent of number of injections per day [5, 6] 
IAsp, insulin aspart; IDeg, insulin degludec; IDegAsp, insulin degludec/insulin aspart.
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Table 2 Summary of the phase 2/3 clinical trials in the insulin degludec/insulin aspart (IDegAsp) clinical programme 
Phase 2 
Reference Study design Patient 
population 
Dosing Comparator HbA1c 
difference 
(95% CI) 
 Hypoglycaemia 
difference 
Weight (kg) Insulin dose 
difference 
Heise et al. 
[28] 
16-week, 
randomised,  
open-label 
T2DM 
(insulin-naïve) 
(n = 178) 
Once daily, 
evening meal 
IDegAsp vs IGlar 
(all + metformin) 
–0.11  
(–0.41; 0.19) 
 IDegAsp 1.2 vs 
IGlar 0.7  
PYE 
Nocturnal 
IDegAsp 1  
IGlar 3 events 
IDegAsp –0.4 ± 
2.3 vs IGlar  
–0.1 ± 3.2 
~20% 
Phase 3 studies in T1DM patients 
Hirsch et al. 
[26] 
26-week, 
randomised,  
open-label,  
treat-to-target 
T1DM 
(n = 548) 
Once daily at 
any meal 
IDegAsp + IAsp 
(at meal-times) 
vs. IDet + IAsp  
(at meal-times) 
–0.05  
(0.18; 0.08) 
 Nocturnal confirmed: 
37% lower IDegAsp vs 
IDet + IAsp 
(p < 0.05) 
 
+2.3 (IDegAsp) 
and +1.3 (IDet), 
respectively  
(p < 0.05) 
13% lower with 
IDegAsp vs IDet 
(p < 0.0001) 
Phase 3 studies in insulin-naïve T2DM patients 
Onishi et al. 
[30] 
26-week,  
open-label,  
treat-to-target 
T2DM 
Japanese 
population 
(n = 296) 
Once daily IDegAsp vs IGlar –0.28 
(–0.46;  
–0.10), 
p < 0.01 
 Overall 0.73  
(95% CI 0.50; 1.08),  
p = NS 
Nocturnal:  
0.75 (95% CI 0.34; 1.64), 
p = NS  
+0.7  
(IDegAsp) 
+ 0.7  
(IGlar) 
0.41 U/kg 
(IDegAsp) 
0.41 U/kg 
(IGlar) 
Franek et al. 
[31] 
26-week, 
randomised, open-
label, multinational, 
parallel-group, 
treat-to-target 
T2DM 
(n = 394) 
Twice daily 
with breakfast 
and main 
evening meal 
IDegAsp vs BIAsp 
30 
1:1 
 
0.02 
(–0.12; 0.17) 
 Confirmed: RR 0.46, 
(95% CI 0.35; 0.61),  
p < 0.001 
Nocturnal: RR 0.25  
(95% CI 0.16; 0.38),  
p < 0.001  
0.79  
(95% CI –0.03; 
1.61) 
0.80 U/kg 
(IDegAsp) 
0.82 U/kg 
(BIAsp 30) 
Phase 3 studies in insulin-experienced T2DM patients 
Fulcher et 
al. [5] 
26-week, 
randomised, open-
label, multinational, 
treat-to-target 
T2DM in a 
global 
population 
(n = 446) 
Twice daily 
with breakfast 
and main 
evening meal 
IDegAsp vs BIAsp 
30 
1:1 
–0.03%  
(–0.18; 0.13)  
 Confirmed:  
0.68 (95% CI 0.52; 0.89),  
p = 0.0049 
–0.62  
(95% CI –1.15; 
 –0.10) 
0.89  
(95% CI 0.83; 
0.96);  
p = 0.002 
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Kaneko et 
al. [6] 
26-week, phase 3, 
open-label, 
randomised,  
treat-to-target 
T2DM 
Hong Kong, 
Japan, 
Malaysia, South 
Korea and 
Taiwan 
(n = 424) 
Twice daily 
with breakfast 
and main 
evening meal 
IDegAsp vs BIAsp 
30 
2:1 
0.05  
(–0.10; 0.20) 
 Severe: 
1.30 (95% CI 0.24; 7.03); 
p = NS 
Nocturnal: 
 0.67 (95% CI 0.43; 
1.06),  
p = NS 
–0.38  
(95% 
CI –0.96; 0.21) 
0.79  
(95% CI 0.73; 
0.85),  
p < 0.0001 
Christiansen 
et al. [32] 
Combined analysis Global vs Asian 
population 
(n = 868) 
Twice daily 
with breakfast 
and the main 
evening meal 
IDegAsp vs BIAsp 
30 
0.00  
(–0.11; 0.10), 
p = 0.96 
 IDegAsp vs 
BIAsp 30: 
Confirmed: RR 0.81 
(95% CI 0.67; 0.98),  
p = 0.03 
Nocturnal: 
0.43 (95% CI 0.31; 0.59), 
p < 0.0001  
Severe: 
0.61 (95% CI 0.26; 1.45), 
p = 0.27  
–0.50 (95% CI  
–0.88; 0.11),  
p = 0.012 
0.84 (0.80; 0.89),  
p < 0.0001 
Rodbard et 
al. [33] 
26-week, 
randomised, 
multinational, 
phase 3b 
T2DM 
(n = 274) 
IDegAsp once 
or twice daily 
(breakfast or 
lunch and 
evening meal) 
or IDeg once 
daily (any time 
of day) + IAsp 
(with a main 
meal 2–4 
times daily) 
IDegAsp twice 
daily vs IDeg + 
IAsp 2–4 times 
daily 
0.18  
(–0.04; 
0.41),  
p = NS 
 Confirmed 
0.81 (95% CI 0.61; 1.07), 
p = NS 
Nocturnal: 0.80, (95% CI 
0.50; 1.29), p = NS 
–1.04 
(95% CI –1.99; 
0.10),  
p < 0.05 
0.88 
 (95% CI 0.78; 
1.00),  
p < 0.05 
BIAsp 30, biphasic insulin aspart 30; CI, confidence interval; HbA1c, glycosylated haemoglobin; IAsp, insulin aspart; IDeg, insulin degludec; IDegAsp, insulin degludec/insulin 
aspart; IDet, insulin detemir; IGlar, insulin glargine; NS, not significant; PYE, patient-years of exposure; RR, rate ratio; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes 
mellitus.  
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Table 3 Clinical guidance for the use of IDegAsp 
FPG, fasting plasma glucose; IAsp, insulin aspart; IDegAsp, insulin degludec/insulin aspart; SmPC, Summary of 
Product Characteristics, U, unit 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The mechanism of action of IDegAsp insulin co-formulation. In the pharmaceutical 
preparation (A), the IDeg component forms soluble di-hexamers at neutral pH, whereas IAsp 
Clinical use of IDegAsp  
Dosing Licensed once or twice daily with main meal(s) 
Timing of meals not important if interval >4 hours 
Timing of meals can vary between days  
Insulin-naïve 
starting dose 
Should be individualised   
Recommended starting dose is 10 U with a main meal, based on clinical trial protocols 
Dose adjustment should be weekly 
If appropriate, additional IAsp dose(s) can be given at other meals 
Combination with oral agents is often optimal 
Prior insulin user 
switching doses 
From full multiple injection regimen: choose dose(s) to keep the total basal dose unchanged 
From premix insulin: keep total dose unchanged 
From basal insulin only: keep total dose unchanged, unless in very poor control when some 
increment may be appropriate 
For all switches, doses should be determined by individual requirements  
Titration Dose adjustments should be based on FPG measurements and hypoglycemia 
A dose-titration algorithm is provided in the IDegAsp European SmPC [12]  
Practical 
advantages 
compared with 
premixed or 
multiple injection 
regimens 
Stable consistent glucose-lowering effect due to ultra-long flat pharmacodynamics of IDeg 
basal component 
Fewer injections leading to a less-complex regimen 
Straightforward dose titration 
Less hypoglycemia in some circumstances, especially nocturnal hypoglycemia 
Dose timing Before any main meal, or combination of main meals (but not within 4 hours), and can be 
varied from day to day 
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remains as distinct hexamers. Upon injection (B), IDeg di-hexamers immediately form stable 
multi-hexamers in the subcutaneous tissue from which IDeg monomers dissociate slowly and 
continuously. IAsp hexamers promptly dissociate to monomers and the depot is thus rapidly 
absorbed into the circulation. IAsp, insulin aspart; IDeg, insulin degludec; IDegAsp, insulin 
degludec/insulin aspart. 
(A) 
 
(B) 
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Figure 2 Differences in mean glucose infusion rate (GIR) profiles of IDegAsp and BIAsp 30. 
GIR profile at steady state following once-daily administration of IDegAsp 0.6 U/kg [14] and 
GIR profile of single-dose BIAsp 30 0.6 U/kg [19]. Both GIR profiles are from studies 
conducted in people with type 1 diabetes mellitus. BIAsp 30, biphasic insulin aspart 30; 
IDegAsp, insulin degludec/insulin aspart. 
 
 
